SelectMDx Posters and Abstracts

Validation of a 2-Gene mRNA Urine Test for Detection of High-Grade Prostate Cancer in German Men 

Summary: In this first validation study of SelectMDx in German men, investigators evaluated the test in men who underwent an initial biopsy to determine SelectMDx’s effectiveness in detecting high-grade, or aggressive, prostate cancer (PCa). The study showed that a SelectMDx result was 95% accurate for ruling out the presence of high-grade PCa and that 46% of potentially unnecessary biopsies could have been avoided if the initial biopsy had been performed based on SelectMDx results alone. 

Presented at The American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), San Francisco, California from February 14, 2019. Moderated poster: Board E20. For full abstract and list of authors, click here.

SelectMDx vs. Prostate Health Index in the Identification of High-Grade Prostate Cancer

Summary: Investigators evaluated the clinical utility of SelectMDx and Prostate Health Index (phi) tests for diagnosis of high-grade PCa as compared with transperineal mapping biopsy (TMB) results. Using multivariate logistic regression analyses, researchers found that SelectMDx was significantly better than phi for diagnosing high-grade PCa. With high sensitivity and negative predictive value, SelectMDx test is more useful than phi for screening patients at risk of high-grade PCa prior to biopsy. 

Presented at The American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), San Francisco, California from February 14, 2019. Moderated poster: Board B18. For full abstract and list of authors, click here.

Cost-Effectiveness of a 2-Gene Urine Biomarker Assay in MRI Strategies for the Initial Detection of Prostate Cancer

Summary: Using a decision-analytic computer model, investigators assessed the cost-effectiveness of SelectMDx by analyzing the test’s use in a population of U.S. men at-risk for prostate cancer prior to and after receiving an MRI. The study found that using SelectMDx prior to an MRI improved health outcomes and saved $1,590 per patient, or approximately $496 million for the yearly population of men at risk in the US. This study shows that the use of SelectMDx to guide prostate biopsy decision-making can significantly improve health outcomes and lower costs. 

Presented at The American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), San Francisco, California from February 14, 2019. Moderated poster: Board E15. For full abstract and list of authors, click here.

SelectMDx vs. Prostate Health Index in the Identification of High-Grade Prostate Cancer

Summary: Investigators evaluated the clinical utility of SelectMDx and Prostate Health Index (phi) tests for diagnosis of high-grade PCa as compared with transperineal mapping biopsy (TMB) results. Using multivariate logistic regression analyses, researchers found that SelectMDx was significantly better than phi for diagnosing high-grade PCa. With high sensitivity and negative predictive value, SelectMDx test is more useful than phi for screening patients at risk of high-grade PCa prior to biopsy.

Presented at The American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), San Francisco, California from February 14, 2019. Moderated poster: Board B18. For full abstract and list of authors, click here.